Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 10/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656173 | 0.89 | ENPP1 (0.80) | ENPP1KDM4EALDH1A1 | |
| SCHEMBL25656164 | 0.84 | ENPP1 (0.78) | ENPP1 | |
| SCHEMBL25656178 | 0.80 | ENPP1 (0.68) | ENPP1KDM4EALDH1A1 | |
| SCHEMBL23762340 | 0.78 | ENPP1 (1.00) | ENPP1 | |
| SCHEMBL25656012 | 0.78 | ENPP1 (0.48) | ENPP1KDM4EPOLBLMNAALDH1A1 | |
| SCHEMBL25656161 | 0.75 | ENPP1 (0.65) | ENPP1 | |
| SCHEMBL25656170 | 0.75 | ENPP1 (0.79) | ENPP1 | |
| SCHEMBL25656010 | 0.74 | ENPP1 (0.63) | ENPP1 | |
| SCHEMBL25656171 | 0.73 | ENPP1 (0.59) | ENPP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23742849 | 0.72 | ENPP1 (1.00) | ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885KDM4E 3611/4885POLB 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.